home / stock / pbla / pbla news

PBLA News and Press, Panbela Therapeutics Inc Com From 04/24/23

Stock Information
Company Name: Panbela Therapeutics Inc Com
Stock Symbol: PBLA
Market: NASDAQ
Website: panbela.com
Menu
PBLA PBLA Quote PBLA Short PBLA News PBLA Articles PBLA Message Board
Get PBLA Alerts

News, Short Squeeze, Breakout and More Instantly...
PBLA - Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023

MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 4, 2023, at 4...
PBLA - Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer

MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces a poster presentation highlighting the results for iv...

PBLA - First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine

MINNEAPOLIS, April 12, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase II double-blind, rand...

PBLA - Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)

MINNEAPOLIS, April 11, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs today announced that it has regained the North American rights ...
PBLA - Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting

MINNEAPOLIS, April 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs today announced that an abstract about CPP-1X (also known as DF...

PBLA - Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting

MINNEAPOLIS, April 06, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract about CPP-1X (also known as DFMO or Eflornithine) ...

PBLA - Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine

MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a new research agreement with the Johns Hopkins University School of ...
PBLA - Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, March 22, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for patent JP 7232845 titled “METHODS ...

PBLA - Panbela Therapeutics, Inc. (PBLA) Q4 2022 Earnings Call Transcript

2023-03-16 19:49:03 ET Panbela Therapeutics, Inc. (PBLA) Q4 2022 Earnings Conference Call March 16, 2023, 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - Chief Executive Officer Sue Horvath - Chief Financial Officer Conference...

PBLA - Panbela Therapeutics GAAP EPS of -$5.68 misses by $2.08

2023-03-16 16:33:07 ET Panbela Therapeutics press release ( NASDAQ: PBLA ): Q4 GAAP EPS of -$5.68 misses by $2.08 . General and administrative expenses were $1.7 million in the fourth quarter of 2022, compared to $1.3 million in the fourth quarter of 2021. Research...
Previous 10 Next 10